Pharmabiz2h
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary: Our Bureau, Mumbai Tuesday, January 7, 2025, 17:15 Hrs [IST] Zydus L ...
Pharmabiz1h
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...
Pharmabiz2h
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease: Hyogo, Japan Tuesday, January 7, 20 ...
Pharmabiz3h
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India
Our Bureau, Mumbai Tuesday, January 7, 2025, 16:45 Hrs [IST] ...
Pharmabiz3h
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...
Pharmabiz4h
RNT Health Insights receives second US FDA breakthrough device designation for esophageal cancer detection tool
RNT Health Insights receives second US FDA breakthrough device designation for esophageal cancer detection tool: Our Bureau, Mumbai Tuesday, January 7, 2025, 15:40 Hrs [IST] RNT H ...
Pharmabiz4h
eMBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available
MBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available: Madison, Wisconsin Tuesday, January 7, 2025, 15:00 Hrs [IST] In a milestone for cel ...
Pharmabiz5h
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...
Pharmabiz7h
Biotech Showcase 2025 is set to convene in San Francisco for Biotech Investor Conference
Biotech Showcase 2025 is set to convene in San Francisco for Biotech Investor Conference: Our Bureau, Mumbai Tuesday, January 7, 2025, 12:00 Hrs [IST] Biotech Showcase 2025, an ex ...
Pharmabiz8h
Claypond Capital appoints Dr Shravan Subramanyam to lead its medical technology platform
Claypond Capital appoints Dr Shravan Subramanyam to lead its medical technology platform: Our Bureau, Bengaluru Tuesday, January 7, 2025, 11:50 Hrs [IST] Claypond Capital, the fam ...
Pharmabiz11h
Indian pharma notes revised Schedule M extension signals key step to avoid closure of units
Indian pharma notes revised Schedule M extension signals key step to avoid closure of units: Nandita Vijayasimha, Bengaluru Tuesday, January 7, 2025, 08:00 Hrs [IST] Indian pharma ...
Pharmabiz8h
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...